Related by context. All words. (Click for frequent words.) 76 Pooled Analysis 75 Meets Primary Endpoint 75 Oral Fingolimod 75 Randomized Phase II 74 First Patient Dosed 74 Phase III Clinical Trial 74 Randomized Double Blind 74 Randomized Study 74 Randomized Phase 73 Prospective Randomized 73 Pivotal Phase 73 Phase 2b Clinical Trial 73 Randomized Phase III 72 Renal Cell Carcinoma 72 Combination REOLYSIN R 72 Controlled Trial 72 Randomized Clinical Trial 72 Study Evaluating 72 Completes Patient Enrollment 72 Clinical Trial Results 71 Initiates Phase II 71 Double Blind Placebo 71 Subgroup Analysis 71 Unfractionated Heparin 71 Phase 2b Trial 71 Multicenter Phase 71 Relapsed Multiple Myeloma 71 Novel Oral 71 Hormone Refractory Prostate Cancer 71 Phase III Pivotal 71 Phase III Trial 71 Initiate Phase III 71 RNAi Therapeutic 71 Combination Treatment 71 Prolongs Survival 71 Spectrum Pharmaceuticals Announces 70 Randomized Double blind 70 Phase IIb Trial 70 Immunomedics Announces 70 Improves Survival 70 Shows Promising 70 Controlled Study 70 Randomized Trials 70 Patient Enrollment 70 Initiate Phase 70 Systemic Delivery 70 Phase III Clinical Trials 70 Randomized Double Blind Placebo 70 Advanced Melanoma 70 Phase 2a Clinical Trial 70 Drug Candidate 70 Initiated Phase 70 Pivotal Phase III 70 Metastatic Melanoma 70 Patients Enrolled 69 Severe Sepsis 69 Disease Progression 69 Autologous Stem Cell Transplantation 69 Pivotal Trial 69 Antitumor Activity 69 Improves Outcomes 69 Gastric Cancer 69 Randomized Clinical Trials 69 Dose Escalation 69 Lung Cancer Trial 69 Trial Evaluating 69 Adjuvant Treatment 69 Acute Ischemic Stroke 69 Relapsing Multiple Sclerosis 69 Completes Enrollment 69 Study Showed 69 Bone Metastases 69 Pharmacokinetic Study 69 Placebo Controlled 69 Initiates Phase III 69 Anti Tumor Activity 69 Demonstrates Sustained 69 Clinical Outcome 69 Patients Treated 69 ST Elevation Myocardial 69 Shows Promise Against 69 II Clinical Trial 69 Eluting Stent 69 Cardiotoxicity 69 Patients Treated With 69 Stent Thrombosis 68 Pivotal Study 68 Heart Failure Patients 68 Adjuvant Chemotherapy 68 Resistant Hypertension 68 Initiates Phase 2b 68 Phase 2a Trial 68 Metastatic Colorectal Cancer 68 Enrolling Patients 68 Proves Effective 68 Commences Phase 68 Efficacy Trial 68 Confirms Efficacy 68 Myeloma Patients 68 Gene Mutation 68 Receives Orphan Drug Designation 68 JAK Inhibitor 68 Diamyd Medical Diamyd 68 Heart Transplant Recipients 68 Anti Tumor 68 Ozarelix 68 Achieves Primary Endpoint 68 Hepatocellular Carcinoma 68 Tyrosine Kinase Inhibitor 68 Successfully Completes Phase 68 Artery Disease 68 Bare Metal Stents 68 Vaccine Adjuvants 68 Drug Shows Promise 68 Pulmonary Arterial Hypertension 68 Patient Outcomes 68 Treating Chronic 68 Recurrent Breast Cancer 68 Investigational Treatment 68 Topline Results 68 Single Dose 68 Complicated Skin 68 NDA Submission 68 Cancer Therapies 67 CYT# potent vascular disrupting 67 Dendritic Cells 67 Clinical Trial Evaluating 67 Placebo Controlled Trial 67 Fungal Infections 67 Nicotine Vaccine 67 Hormone Receptor Positive 67 Randomized Placebo controlled 67 Lung Cancer Survival 67 Newly Diagnosed Multiple Myeloma 67 Nilotinib 67 Cardiovascular Outcomes 67 Breast Cancer Recurrence 67 Demonstrates Positive 67 Oral Calcitonin 67 Randomized Controlled 67 Malignant Melanoma 67 Dose Ranging 67 Sapacitabine 67 Hypertensive Patients 67 Phase 1b Clinical Trial 67 Brain Metastases 67 Phase IIb Clinical Trial 67 Randomized Evaluation 67 Bazedoxifene 67 Dose Ranging Study 67 Chronic Hepatitis C 67 Inhaled Corticosteroids 67 Patients Receiving 67 Radiofrequency Ablation 67 Glufosfamide 67 Perifosine KRX 67 Investigational Drug 67 Improve Survival 67 Carotid Stenting 67 Catheter Ablation 67 Commence Phase 67 Neovascular Age Related Macular 67 Sangamo BioSciences Announces 67 Nuvelo Announces 67 Randomised 67 Safinamide 67 Hsp# Inhibitor 67 Intracranial Aneurysms 67 Preclinical Study 67 Initiates Clinical Trial 67 Acute Myocardial Infarction 67 Gout Drug 67 Initiate Phase II 67 Blind Placebo Controlled 67 Confirmatory Phase 67 Chronic Myeloid Leukemia 67 Second Pivotal Phase 67 Prospective Multicenter 67 Inflammatory Markers 67 Pivotal Clinical Trial 67 Advanced Renal Cell 67 Advanced Colorectal Cancer 67 Anticancer Drug 67 Gastrointestinal Stromal Tumors 67 Initiates Enrollment 67 Anticancer Drugs 67 Diabetic Macular Edema 66 IND Filing 66 Drug Prevents 66 Phase 2b Study 66 Metastatic Prostate Cancer 66 Peginterferon Alfa 2a 66 Prophylactic Treatment 66 Ovarian Cancer Screening 66 Randomized Controlled Trials 66 Prosecution Rests Case 66 Innate Immune 66 Rigel R# 66 Tumor Response 66 Ischemic 66 First Patient Enrolled 66 Transdermal Patch 66 registrational Phase 66 Anti CD# Antibody 66 Malignant Glioma 66 Mouse Model 66 Stent Restenosis 66 Naive Patients 66 Refractory Angina 66 Advanced Prostate Cancer 66 Vascular Inflammation 66 Placebo Controlled Study 66 IIa Clinical Trial 66 Shows Efficacy 66 Colorectal Cancer Patients 66 Treatment Naive Patients 66 Drug Combo 66 Phase III Pivotal Trial 66 Cervical Dysplasia 66 Medullary Thyroid Cancer 66 evaluating mipomersen 66 Survival Benefit 66 Previously Untreated 66 Prospective Randomized Trial 66 Vaccine Candidate 66 Tumor Targeting 66 Desvenlafaxine Succinate 66 Custirsen 66 Inhaled Nitric Oxide 66 Anthrax Toxin 66 Adjuvant Breast Cancer 66 Avian Flu Vaccine 66 Molecular Diagnostic Test 66 Hospital Acquired Pneumonia 66 Demonstrates Significant 66 Patients Undergoing 66 Platelet Inhibition 66 CCX# B 66 Infarct 66 Multicenter 66 Monoclonal Antibody 66 Predict Risk 66 HCV Protease Inhibitor 66 Multicenter Randomized Double 66 Demonstrates Efficacy 66 Lowers Risk 66 Fixed Dose 66 Soft Tissue Sarcoma 66 Initiates Phase 66 Lung Cancer Vaccine 66 Phase III Trials 66 Multicenter Trial 66 Balloon Angioplasty 66 Mg Usa 66 Aliskiren 66 AnaSpec Introduces 66 Combination Therapy 66 Follicular Lymphoma 66 Genes Predict 66 Aneurysm Repair 66 First Patient Treated 66 Metastatic Renal Cell Carcinoma 66 Bare Metal Stent 66 Antithrombin 66 Stem Cell Treatment 66 Treatment Shows Promise 66 HDAC Inhibitor 66 Genes Identified 66 ST Segment Elevation 66 Postmenopausal Osteoporosis 66 Allergic Rhinitis 66 Preclinical Data 66 Chronic Hepatitis B 66 Synthetic Peptide 66 Novel Antibiotic 66 Drug Eluting Coronary Stent 66 Skeletal Muscle 66 Adjuvant Therapy 66 Atypical Hemolytic Uremic Syndrome 66 Ischemic Stroke 66 Neuroprotection 65 Telik Announces 65 Benign Prostatic Hyperplasia 65 Experimental Vaccine 65 Treatment Naïve 65 Lung Cancers 65 Multicenter Study 65 Investigational Compound 65 Chronic Liver Disease 65 Diabetic Neuropathic Pain 65 Ranolazine 65 Pivotal Phase II 65 Immunosuppression 65 Tezampanel 65 Non Inferiority 65 Lung Cancer Patients 65 Antiviral Activity 65 Lupus Drug 65 Peginterferon Alfa 2b 65 DIRECT Trial 65 Pediatric Patients 65 Therapeutic Efficacy 65 Oral Anticoagulant 65 familial amyloidotic polyneuropathy FAP 65 Initiates Clinical Trials 65 Cloretazine ® 65 Kinase Inhibitors 65 Gentium Announces 65 Novel Mechanism 65 Previously Treated 65 Relapsing Remitting Multiple Sclerosis 65 Cholesterol Lowering Drug 65 Elderly Patients 65 Cytotoxicity 65 Laryngeal Cancer 65 Kinase Inhibitor 65 Collaborators Present 65 Antigen Specific 65 novel VDA molecule 65 Breast Density 65 Protease Inhibitor 65 Preterm Delivery 65 Diabetic Nephropathy 65 Paroxysmal Atrial Fibrillation 65 Teva Provides Update 65 Secondary Hyperparathyroidism 65 Synta Announces 65 Small Molecule 65 Cardiovascular Events 65 Intra Arterial 65 Treatment Reduces 65 Hepatitis C Infection 65 HER2 Positive 65 Mimetics 65 Randomized Controlled Trial 65 Opening Arguments Begin 65 Therapeutic Vaccine 65 Tumor Growth 65 Spinal Fractures 65 Slows Progression 65 Prognostic Significance 65 Epidermal Growth Factor Receptor 65 Serious Infections 65 By JENNIFER LEARN 65 Myocardial Infarction Study 65 Vaccine Adjuvant 65 Double Blind Randomized 65 Unresectable 65 Prostate Cancer Vaccine 65 Vertebral Fracture 65 Recombinant Protein 65 Meta Analysis 65 Sleep Disturbances 65 Diabetic Patients 65 Autoimmune Disease 65 Files IND 65 Non Alcoholic Steatohepatitis 65 Closing Arguments Heard 65 Novel Compounds 65 Endothelial Cells 65 Insulin Resistance 65 Treatment Experienced 65 Circulating Tumor Cells 65 Investigational Agent 65 Smooth Muscle 65 Diabetic Foot Ulcers 65 Renal Cancer 65 Brentuximab Vedotin SGN 65 Pegylated Liposomal Doxorubicin 65 Shown Effective 65 Signaling Pathway 65 Hematological Cancers 65 Neoadjuvant Chemotherapy 65 Drug Resistant 65 Castration Resistant Prostate Cancer 65 Enlarged Prostate 65 dependent kinase inhibitor 65 Thyroid Hormone 65 Vicriviroc 65 Insulin Glargine 65 LymphoStat B belimumab 65 Sirolimus Eluting Stent 65 Anticancer Activity 65 Ovarian Cancer Patients 65 Refractory Hodgkin Lymphoma 65 J Antimicrob Chemother 65 Diabetic Neuropathy 65 Oral Insulin 65 Virus Infection 65 Treatment Resistant 65 Chronic Lymphocytic Leukemia 65 Appears Safe 65 Rheumatoid Arthritis Drug 65 MEK Inhibitor 65 See CLINICAL PHARMACOLOGY 65 TB Vaccine 65 Phase III AFFIRM 65 Replacement Therapy 65 Demonstrate Significant 65 Viral Suppression 65 Significantly Improves 65 Recurrent Glioblastoma 65 RNAi Therapeutics 65 Lung Cancer Drug 65 Patient Accrual 65 Rheumatoid Arthritis Patients 64 Monoclonal Antibodies 64 multicentre randomized controlled 64 Analytical Tool 64 Fracture Risk 64 Overactive Bladder 64 Delcath Phase III 64 Left Ventricular 64 Knee Osteoarthritis 64 Phase Ib II 64 Viral Infections 64 Critically Ill Patients 64 Nymox NX 64 Statin Therapy 64 Peginterferon 64 assessing T DM1 64 kidney urologic 64 Magnetic Nanoparticles 64 TAXUS ATLAS 64 LUX Lung 64 Microplasmin 64 Telaprevir VX 64 Helps Predict 64 Hepatitis C Genotype 64 Prostate AdenoCarcinoma Treatment 64 Malaria Vaccine 64 Infected Patients 64 Initiate Clinical Trial 64 Neoadjuvant 64 Genetic Variant 64 Study Shows Promise 64 Chronic Heart Failure 64 Septic Shock 64 Pivotal Trials 64 Hedgehog Pathway 64 Immune Cell 64 RECORD1 64 BRIM2 64 Levels Linked 64 Cardiac Biomarkers 64 Left Ventricular Hypertrophy 64 Epilepsy Drug 64 Magnetic Stimulation 64 ALN HPN 64 Patients Suffering 64 Antifungals 64 Brain Aneurysms 64 Visceral Fat 64 Drug Eluting Stent 64 Postmenopausal Women 64 Immunotherapeutic 64 CALERIE 64 Aortic Stenosis 64 Carboplatin Paclitaxel 64 Antitumor 64 Cutaneous T 64 Renal Function 64 Surgery Performed 64 Vaccine Protects Against 64 Combination Clinical Trial 64 Clinical Trials Update 64 Multiple Myeloma Patients 64 Progenitor Cells 64 multicenter phase 64 fosbretabulin 64 Transplant Patients 64 Genes Linked 64 Anthracycline 64 Dose Response 64 Stomach Cancer 64 Present Preclinical Data 64 Vitro Activity 64 Radical Prostatectomy 64 MKC# MT 64 Ibritumomab Tiuxetan 64 Anti Angiogenesis 64 Universal Flu Vaccine 64 Asthma Treatment 64 Prostate Cancer Survival 64 Bayer HealthCare Onyx Pharmaceuticals 64 HCV SPRINT 64 Pafuramidine 64 Mylan Receives Approval 64 Novel Peptide 64 Adenoviral 64 Targeted Therapy 64 Postmenopausal Hormone Therapy 64 Bivalirudin 64 Mycophenolate Mofetil 64 Treat Anemia 64 Atopic Dermatitis 64 Jury Deliberations Begin 64 Stent Coating 64 Unstable Angina 64 Randomised Trial 64 Onyx Pharmaceuticals Announces 64 AVI BioPharma Announces 64 Myocardial Ischemia 64 Clinical Evaluation 64 Aptamer 64 Organ Rejection 64 Guidelines Issued 64 Genetic Variations 64 FDA Okays 64 Orally Active 64 Monotherapy 64 CLARITY TIMI 64 Obese Patients 64 Chemotherapeutic Agents 64 Cholesterol Levels SPARCL 64 Bosutinib 64 Clinical Trial Data 64 Statistically Significant 64 Novel Inhibitor 64 Prostate Cancer Recurrence 64 Novel Therapeutic 64 Radiation Induced 64 pralatrexate injection folate analogue 64 Plaque Psoriasis 64 Prostate Cancer Progression 64 Respiratory Virus 64 Long Lesion 64 Test Detects 64 Coronary Arteries 64 relapsed MM 64 Phase Ib Clinical Trial 64 Long Term Efficacy 64 Total Knee Arthroplasty 64 Prostate Cancer Patients 64 Intravitreal 64 Lymphocytic 64 agonistic human 64 Endovascular Treatment 64 Clinical Efficacy 64 Advanced Ovarian Cancer 64 Novel Method 64 Hypertrophy 64 TKB# 64 Molecular Diagnostic 64 Increased Mortality 64 Deforolimus 64 Phase IIA 64 Bevacizumab 64 Relapsed Refractory 64 Ovarian Cancer Treatment 64 Osteoporosis Treatment 64 Is Well Tolerated 64 Interferon Alpha 64 Therapy Evaluation 64 Vidaza ® 64 Tipranavir 64 Zoledronic Acid 64 Phenotypes 64 Seasonal Influenza Vaccine 64 PROSTASCINT R 64 Dupuytren Contracture 64 evaluating tivozanib 64 Phase IIIb 64 Lung Tumors 64 Acute Myocardial 64 Initiates Clinical 64 Preclinical Efficacy 64 Randomized Placebo Controlled 64 Omacetaxine 64 Eye Diseases 64 ENDEAVOR IV 64 Therapeutic Targets 64 Completes Dosing 64 Risk Stratification 64 Subtypes 63 Protein Linked 63 Intravascular 63 Occlusive Disease 63 Advanced Pancreatic Cancer 63 JAK2 Inhibitor 63 Cardiac Resynchronization 63 Leukemias 63 Male Contraceptive 63 Fulvestrant 63 Treated Patients 63 Implantable Device 63 Breast Tumors 63 Stem Cell Transplants 63 Less Invasive 63 induced macular edema 63 Parathyroid Hormone 63 myocardial infarction ventricular fibrillation 63 Successfully Treated 63 Tuberculosis Vaccine 63 Antiviral Drugs 63 Inflammatory Disease 63 Carcinomas 63 Preclinical Evaluation 63 Develop Novel 63 Val HeFT 63 Demonstrates Potent 63 Milestone Payment 63 Remission Maintenance 63 5 Fluorouracil 63 Intervention Effectiveness 63 Pharmacyclics Announces 63 Cyclophosphamide 63 Antiviral Therapy 63 Node Positive 63 Safety Tolerability 63 Localized Prostate Cancer 63 Antibody Drug Conjugate 63 Mouse Models 63 Solid Tumors 63 Cancer Treatments 63 Plus Ribavirin 63 Sustained Efficacy 63 Epratuzumab 63 Neuroendocrine Tumors 63 Fewer Side Effects 63 Beneficial Effects 63 Influenza Virus 63 Molecular Mechanism 63 Phase IIIb clinical 63 Moderate Drinking 63 Melphalan 63 Pre Cancerous 63 Successfully Treats 63 Inflammatory Arthritis 63 Targeted Therapies 63 Pneumococcal Vaccine 63 Protein Expression 63 Well Tolerated 63 Biomarker Study 63 Chronic HCV 63 Elotuzumab 63 treatment naïve genotype 63 PSMA ADC 63 Versus Placebo 63 Improve Outcomes 63 Treatment Regimen 63 Slow Progression 63 NMDA Receptor 63 Improved Survival 63 multicenter multinational 63 Genes Associated 63 Nebulized 63 Artificial Liver 63 Prolongs Life 63 AVN# Phase 63 Cetrorelix 63 Inhibits 63 Systematic Review 63 Bone Marrow Cells 63 Invasive Fungal Infections 63 Cognitive Function 63 Uterine Cancer 63 Cholinesterase Inhibitors 63 Sipuleucel T 63 Patient Enrolment 63 Oral Insulin Capsule 63 Diabetic Foot Ulcer 63 Newly Diagnosed Patients 63 Immunomodulatory 63 Colorectal Cancers 63 Severe Asthma 63 FOLOTYN ® 63 NSABP B 63 Study Demonstrates 63 Leukemia Cells 63 Pre Exposure Prophylaxis 63 Immune Responses 63 Drug Fails 63 C1 Inhibitor 63 Schizophrenia Drug 63 Vaccine Shows Promise 63 Aggressive Prostate Cancer 63 Primary Hypercholesterolemia 63 DNA Methylation 63 Hepatitis C Virus 63 recurrent metastatic ovarian cancer 63 Pertuzumab 63 Genetic Markers 63 Decompensated Heart Failure 63 Controlled Clinical Trial 63 Liver Tumors 63 Systemic Sclerosis 63 Myelodysplastic Syndromes 63 Bipolar Depression 63 Aflibercept 63 Artificial Pancreas 63 Valsartan 63 Prostate Cancer Prevention 63 Lung Injury 63 Minimally Invasive Treatment 63 Clostridium difficile Infection 63 Presents Positive 63 Antibiotic Resistant 63 Multicenter Double 63 NAVISTAR R 63 oral prodrug 63 MKC# MKC# PP 63 STRIDE PD 63 BRIM3 63 recombinant PSMA vaccine 63 Acute Heart Failure 63 Pharmaceuticals Initiates 63 Decitabine 63 Shows Statistically Significant 63 Dose Finding 63 Mitral Valve Repair 63 Novel Compound 63 Symptom Relief 63 Vaccine Prevents 63 Presents Preclinical Data 63 Factor Receptor 63 Patent Covering 63 Blood Pressure Drug 63 Cardiac Function 63 Vertebral Fractures 63 Phase Ib IIa 63 Image Guided 63 TMC# C# 63 multicenter randomized Phase III 63 Valvular Heart Disease 63 Multicenter Automatic Defibrillator Implantation 63 Glycemic Control 63 Diabetic Kidney Disease 63 Kidney Transplant Patients 63 lexidronam injection 63 Recombinant Human 63 Endothelial Function 63 ORLive Presents 63 p# biomarker 63 Intravesical 63 Signaling Pathways 63 complement inhibitor eculizumab 63 Gene Variation 63 Hematology Molecular Pathology 63 Cognitive Impairment 63 Aggressive Reduction 63 Adefovir 63 INSPIRE Trial Phase III 63 Systolic Blood Pressure 63 Hospitalized Patients 63 Androgen Deprivation Therapy 63 Chronic Inflammation 63 Anti Angiogenic 63 Prostate Tumors 63 dose escalation clinical 63 Abstracts Accepted 63 TRANSDUR ™ 63 Long Term Outcomes 63 Phase IIa Clinical Trial 63 Rotavirus Vaccine 63 Effectively Treats 63 Prospective Randomized Study 63 Polyneuropathy 63 National Emphysema Treatment 63 Nephrol Dial Transplant 63 Reduces Mortality 63 Osteoporosis Drug 63 Infectious Disease Testing 63 Therapeutic Effects 63 Inflammatory Response 63 Breast Cancer Metastasis 63 Holds Promise 63 Degarelix 63 EURIDIS 63 Novel Vaccine 63 J Am Coll 63 Prevent Heart 63 Oral Mucositis 63 Temsirolimus 63 Lupus Nephritis 63 AAG geldanamycin analog 63 siRNA Delivery 63 Cardiac Arrhythmias 63 Antiangiogenic 63 Chronic Sinusitis 63 Trandolapril 63 Drug Coated Stent 63 Peripheral Arterial 62 Drug Eluting 62 Cerebrospinal Fluid 62 Mesothelioma Treatment 62 Ridaforolimus 62 Fondaparinux 62 Blood Pressure Lowering 62 Clinical Antipsychotic Trials 62 Clot Busting 62 REMINDER ORLive Presents 62 Acute Coronary Syndromes 62 Oncolytic Reovirus 62 Sirolimus Eluting 62 placebo controlled Phase III 62 Tissue Engineered 62 CAMMS# 62 multicenter placebo controlled 62 Therapeutic Antibodies 62 Helps Smokers Quit 62 Blood Cancers 62 Cardiac Resynchronization Therapy 62 Crit Rev 62 Proven Effective 62 Pathogen Detection 62 Iron Overload 62 Prognostic Factors 62 Insulin Sensitivity 62 OMP #R# 62 Stable Coronary Artery 62 Dasatinib 62 Premature Infants 62 Medoxomil 62 Elagolix 62 Valopicitabine 62 Humanized Anti 62 Oral Interferon 62 Oral Cladribine 62 MIVI III 62 Liposomal 62 Phase III Psoriasis 62 Carotid 62 TO AVOID PREGNANCY WHILE 62 phase Ib clinical 62 Treatment Naive 62 Stereotactic Body Radiation Therapy 62 NCCTG N# 62 Interferon Gamma 62 PROSTVAC VF 62 Newly Diagnosed 62 Gene Variants 62 Cancer Stem Cells 62 Technological Advances 62 Genetic Variation 62 Preterm Labor 62 Transcription Factor 62 THAT ARE DIFFICULT TO 62 Oncolytic 62 Liver Cancer 62 Venous Thromboembolism 62 multicenter randomized placebo controlled 62 Late Breaker 62 Enzastaurin 62 Folfox 62 HER2 Positive Breast Cancer 62 Clinical Validation 62 PEGylated interferon beta 1a 62 Expanded Indication 62 Kidney Function 62 Trastuzumab DM1 62 Bone Fractures 62 Critical Limb Ischemia 62 Phase #b/#a clinical 62 Huggins Cams Time 62 Anti Inflammatory Drug 62 Unstable Angina Non 62 Bucindolol 62 Liver Metastases 62 Significantly Improved 62 Aurora Kinase 62 Postdoctoral Position 62 Progressive Multifocal Leukoencephalopathy 62 Tesamorelin 62 Pemetrexed 62 ARRY # 62 Low Dose 62 Diffuse Large B 62 Genetic Variants 62 atypical Hemolytic Uremic Syndrome 62 Anticancer Compound 62 targeting miR 62 Urinary Incontinence 62 Breast Tumor 62 Tumor Progression 62 Thromboembolic 62 Novel Therapies 62 Acute Decompensated Heart Failure 62 Thromboembolism 62 Stenting 62 FDA Approves Drug 62 Therapeutic Vaccines 62 EXPLORE Xa 62 Shows Promise 62 ABCSG 62 Gene Variant 62 Abstract Accepted 62 blinded randomized placebo controlled 62 Bucindolol Based 62 Cocaine Addiction 62 SUTENT ® 62 Hepatitis C Virus HCV 62 Autoimmune Diseases 62 Non Alcoholic Fatty 62 Proves Successful 62 Aeolus Pharmaceuticals Announces 62 R lenalidomide 62 Protein Interaction 62 Uterine Fibroid Embolization 62 NMT Medical Announces 62 VIVITROL ® 62 candidates Augment ™ 62 AEG# 62 multicentre randomized 62 Further Validates 62 Hepatocellular 62 cisplatin gemcitabine 62 multicenter Phase III 62 Study Shows Benefits 62 Genetic Marker 62 Smoking Linked 62 Biolimus A9 62 Advaxis Phase 62 Renal Tumors 62 Coronary Artery Calcium 62 Patient Treated 62 Dyslipidemia 62 Demonstrates Potential 62 Pemphigus Vulgaris 62 Surgical Treatment 62 ALN TTR 62 phase IIb clinical 62 Vaginal Gel 62 Diabetic Ulcers 62 Postmenopausal 62 Renal Impairment 62 relapsing remitting MS RRMS 62 Begin Clinical Trials 62 Intracerebral Hemorrhage 62 Strongly Linked 62 EQUATE OB 62 Cardiovascular Risk Reduction 62 Therapy Reduces 62 Neurocrine Biosciences Announces 62 Stable Angina 62 undergoing elective percutaneous 62 Cholesterol Drug 62 virus HCV protease inhibitor 62 unfractionated heparin UFH 62 CYP#A# substrate 62 Angiogenic 62 Prostate Cancer Treatment 62 Protein Structures 62 Eculizumab 62 Breast Cancers 62 Blind Placebo Controlled Trial 62 Carcinoma 62 IMPACT DCM 62 Endometrial Cancer 62 Potent Antiviral Activity 62 Therapeutic Antibody 62 Motesanib 62 Premenopausal Women 62 Reperfusion Injury 62 Poniard Pharmaceuticals Announces 62 Therapy Improves 62 multicenter randomized controlled 62 Venous Thrombosis 62 Gene Linked 62 Osteoarthritis Patients 62 Sustained Reduction 62 Colorectal Adenomas 62 Bloodstream Infections 62 Enzyme Replacement Therapy 62 Initiates Dosing 62 Renal Cell Cancer 62 Reduces Pain 62 Sorafenib HCC Assessment 62 Myelodysplastic Syndrome MDS 62 Phase Ib clinical 62 Hyperlipidemia 62 Outpatient Setting 62 Cell Lymphoma 62 Lymph Node 62 intravesical infusion therapy 62 Viral Load 62 Pirfenidone 62 Polymerase Inhibitor 62 Ebola Vaccine 62 Antiplatelet 62 Hepatitis C Antiviral 62 Crofelemer budesonide foam 62 Oral Formulation 62 Embolization 62 Patency 62 Hepatitis B Virus 62 Prognostic Value 62 Lowering Blood Pressure 62 Antidepressants Linked 62 Regimens 62 Nephropathy 62 Proc Am Soc 62 Tiotropium 62 TRANSFORMS 62 Irbesartan 62 Protein Synthesis 62 includes TOLAMBA TM 62 Thrombotic 62 Clinical Outcomes